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Abstract
Background: While the home is the most common setting for the provision of palliative care in Australia, a
common problem encountered here is the inability of patient/carers to manage medications, which can lead to
misadventure and hospitalisation. This can be averted through detection and resolution of drug related problems
(DRPs) by a pharmacist; however, they are rarely included as members of the palliative care team. The aim of this
study was to pilot a model of care that supports the role of a pharmacist in a community palliative care team. A
component of the study was to develop a cost-effective model for continuing the inclusion of a pharmacist within
a community palliative care service.
Methods: The study was undertaken (February March 2009-June 2010) in three phases. Development (Phase 1)
involved a literature review; scoping the pharmacist’s role; creating tools for recording DRPs and interventions, a
communication and education strategy, a care pathway and evidence based patient information. These were then
implemented in Phase 2. Evaluation (Phase 3) of the impact of the pharmacist’s role from the perspectives of team
members was undertaken using an online survey and focus group. Impact on clinical outcomes was determined
by the number of patients screened to assess their risk of medication misadventure, as well as the number of
medication reviews and interventions performed to resolve DRPs.
Results: The pharmacist screened most patients (88.4%, 373/422) referred to the palliative care service to assess
their risk of medication misadventure, and undertook 52 home visits. Medication reviews were commonly
conducted at the majority of home visits (88%, 46/52), and a variety of DRPs (113) were detected at this point, the
most common being “patient requests drug information” (25%, 28/113) and “condition not adequately treated”
(22%, 25/113). The pharmacist made 120 recommendations in relation to her interventions.
Fifty percent of online survey respondents (10/20) had interacted 10 or more times with the pharmacist for advice.
All felt that the pharmacist’s role was helpful, improving their knowledge of the different medications used in
palliative care. The six team members who participated in the focus group indicated that there were several
benefits of the pharmacist’s contributions towards medication screening and review.
Conclusions: The inclusion of a pharmacist in a community palliative care team lead to an increase in the
medication-related knowledge and skills of its members, improved patients’ medication management, and
minimised related errors. The model of care created can potentially be duplicated by other palliative care services,
although its cost-effectiveness was unable to be accurately tested within the study.
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Approximately 50 to 90% of cancer patients, and 9 to
16% of non-cancer patients, are referred into palliative
care services per 100, 000 population per year in Austra-
lia [1]. Palliative care service provision occurs in three
settings: in the community, in designated palliative care
or hospice facilities, and within acute care hospitals.
Community settings include the patient’sh o m eo ra
community living environment such as an aged or sup-
ported care facility [2]. Home is the most common set-
ting, where approximately 70 to 80% of patients receive
palliative care [3], with a significant proportion choosing
to die at home [2].
A common problem encountered in the home is the
inability to adequately manage medications, which is a
significant issue given that they are used to treat symp-
toms experienced by the patient, such as pain. Inadequate
medication management often stems from poor medica-
tion-related knowledge and understanding, in other
words, health literacy [4,5], and can lead to non-concor-
dance with medication regimens - medications not being
taken, taken the wrong way or in the wrong dose, which
can result in substantial treatment issues for the patient
with impacts on their quality of life. The palliative care
population has been identified as one of the groups who
are at the highest risk of medication misadventure and
adverse events, and consequently hospital admissions [6].
In particular, this is an unfavourable outcome when high
risk medications such as opioids are involved, which are
strong in potency, required to be taken chronically and
have a high incidence of significant side effects such as
constipation, drowsiness and nausea.
Further compounding this problem is the lack of con-
sumer-oriented clinical information on medications.
This is especially important as medications that patients
needing palliative care take are for reasons and doses
different to that described in information produced by
pharmaceutical manufacturers, known as consumer
medicine information (CMI) in Australia. This informa-
tion is brand-specific and is based on the manufacturer’s
approved usage of the medication. However, as it is too
complex for patients and carers to understand and does
not cater to the educational needs of those from non-
English speaking backgrounds [5,7], patients and carers
are left with no choice but to search other primary and
secondary sources of information such as the Internet
[7], that are not pre-assessed to determine their level of
evidence, and could result in patients opting for treat-
ments that are not appropriate and potentially cause
harmful outcomes.
Such problems also result in indirect expenditures,
such as psychological, social and economic burdens on
patients, carers and the healthcare system, which are gen-
erally much greater than the costs of pharmacological
and non-pharmacological treatments [2,8]. The palliative
care health team is in an ideal position to address and
curb these issues in a timely manner, so that their effects
are minimised. Quality of care is enhanced when patients
a r ea b l et ob et r e a t e db yat e a mt h a tc o m p r i s e sav a r i e t y
of health professionals, each with their own set of knowl-
edge, skills and experience. This includes, but is not lim-
ited to, specialised medical and nursing staff, and allied
health professionals such as physiotherapists, music
therapists, pastoral care workers, occupational therapists,
pharmacists and counselling professionals [1].
Pharmacists, however, are not widely recognised as
members of the palliative care health team [2,9,10]. The
pharmacist is an integral team member whose contribu-
tions can potentially improve the patient’s medication
management and reduce their risk of non-concordance
and hospital admissions [11]. Hussainy (2007) has indi-
cated, however, that the pharmacist has other roles beyond
medication management [8]. In a recent study by Wilson
(2011), the majority of pharmacists’ recommendations
were accepted by physicians, and most patients achieved
the desired clinical outcome - improvement or resolution
of the presenting symptom. The pharmacist’s recommen-
dation, the recommending pharmacist, and closer proxi-
mity to death were found to be significant predictors of
achieving the desired clinical outcome [12]. This highlights
that acceptance and acknowledgement of the pharmacist’s
expertise in medication management is essential for sup-
porting their role in a team.
In Australia, the role of a pharmacist in a community
multidisciplinary palliative care team had not previously
been piloted and a model of care to support and opti-
mise this had not been developed and trialled. The over-
all aim of this study therefore was to develop a model of
care that supports the role of a pharmacist as a member
of a community palliative care multidisciplinary team
(called “the team” hereon) and is potentially cost-effec-
tive, to improve outcomes for patients at home and
their carers. Specifically, the pharmacist’sr o l ew a st o
assist in improving knowledge of medications and their
management for the health professionals within the
team, and for patients and their carers. A major thrust
was to minimise medication misadventure and, where
possible, to reduce hospital admissions and lower costs
to the service system.
The team operated within a service that is a member
of the Southern Metropolitan Region Palliative Care
Consortium (SMRPCC, http://www.smrpalliativecare-
consortium.org.au) in Melbourne, Australia. The service
provides specialist palliative care and neurological care
in the community, covering a population base of over
500, 000. Patients may be referred by their carers, gen-
eral practitioners (GPs), other health care professionals,
external agencies, or by self-referral. The service admits
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patients on the program at any one time. Patients’ ages
range from 1-90+ years (median age 65+), and approxi-
mately 85% have a malignant diagnosis and 15% non-
malignant, including end stage Motor Neurone Disease.
Prior to the integration of the pharmacist (known as the
“Project Pharmacist” hereon) in to the team, it provided
specialist medical, nursing, allied health, pastoral care,
and bereavement services with the support of trained
volunteers.
Methods
The study was undertaken from February 2009 to June
2010 in three key phases described below. Approval by
the ethics committee at the palliative care service was
not required as the work undertaken in this study was
deemed to be part of an ongoing quality improvement
service to patients and their carers/families.
Phase 1: Development
The objective of this phase was to develop various activ-
ities, namely pathways/strategies and tools, informed by
information in the literature, which the Project Pharma-
cist (S.S) could use and follow when collecting data, col-
laborating with other members in the palliative care
team, and interacting with patients and carers.
Literature review
A literature review was commenced in this phase and
continued throughout the study, to provide a framework
for the Project Pharmacist’s role. Five areas were investi-
gated, the results of which are reported elsewhere [5]:
medication reviews; prescribing in palliative care; inter-
ventions; patient/consumer information; and patients at
risk of non-concordance.
Project Pharmacist’s role
Based on the findings of the literature review and with
advice and support from the following people, the Pro-
ject Pharmacist’s role was developed:
￿ Project Team (which was separate to the team
above and comprised an Allied Health Manager,
Director of Clinical Services, Chief Pharmacist who
provided inpatient services, Team Leaders and Pro-
ject Manager - M.B)
￿ External Evaluator (S.H) who is a pharmacist with
palliative care expertise
￿ Steering Committee that was established
￿ Key stakeholders from various organisations/
networks
Tools
To assist the Project Pharmacist in undertaking their
role, various tools were developed/adapted, based on the
findings of the literature review.
The Medication review screening tool (MRST, see
additional file 1) was developed to help determine if the
patient is ‘at risk’ of medication misadventure and
record other information such as diagnosis, allergies/
adverse drug reactions, and renal and hepatic function.
This tool was based on the “Home Medicines Review
(HMR) Referral” [13], which the general practitioner
(GP) uses to facilitate a HMR for a patient in their
home, as well as other literature [14-16]. However, the
MRST was developed to capture other risk factors than
those in the HMR referral, as the majority of patients
being palliated would be eligible for a HMR based on
the criteria in the HMR referral.
The Intervention tool (see additional file 2) was
adapted from “D.O.C.U.M.E.N.T (Drug selection, Over
or underdose prescribed, Compliance, Untreated indica-
tions, Monitoring required, Education or Information,
Non-clinical, and Toxicity or adverse reaction) for Med-
ication Review” [17], to assist the Project Pharmacist in
documenting drug related problems (DRPs) and recom-
mendations made to resolve them (both descriptions
and classifications of these).
Project Pharmacist’s Activity Database
A database was developed so that the Project Pharma-
cist could log her activities and enter in data collected
using the MRST and Intervention tool.
Care pathway
A care pathway was developed to assist members of the
team in better managing patients.
Where a patient was referred to the service, this path-
way involved a nursing admission assessment being
undertaken first, prior to the patient’s case being pre-
sented at the weekly team meeting. Based on knowledge
gained at the team meeting, the patient’sh i s t o r ya n d
referral documentation, the Project Pharmacist then
conducted an initial medication screening using the
MRST. If the MRST found the patient to be ‘at risk’ of
medication misadventure, the Project Pharmacist was
available to conduct a medication review.
The Project Pharmacist was available to undertake the
medication review on admission, when visiting the
patient in their home with the Community Nurse at
admission (at discretion of one of the Team Leaders), or
later in the patient’s home if deemed appropriate by a
team member.
Where a patient was discharged from the inpatient ser-
vice (hospital) to home and referred to the Project Phar-
macist, she visited the patient prior to discharge and
informed them that a home visit could be organised
within 7-10 days after discharge. In this scenario, the
Project Pharmacist performed an outreach medication
review.
Where a patient was discharged from another hospital
to home and referred to the Project Pharmacist,s h e
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within the same time frame and conduct an outreach
medication review.
All referrals were made using a standardised Referral
Form that was developed.
Following medication review by the Project Pharma-
cist, the patient’s treatment plan was updated and the
Project Pharmacist provided feedback to the team, the
patient’s GP, and community pharmacy as necessary in
the form of a Medication Review Report.
Evidence based patient information
Patient information leaflets (PILs) on the following nine
medications used in palliative care in were developed:
clonazepam; cyclizine; fentanyl; gabapentin; hydromor-
phone; metoclopramide; morphine; oxycodone; and
pregabalin.
The morphine leaflet was piloted for face and content
v a l i d i t yb yas a m p l eo fp a t i e n t sa n dc a r e r s ,d o c t o r s ,t h e
team and volunteers from the palliative care service
(including an ex-pharmacist and people from a non-
English speaking background). Based on the informa-
tion, most patients/carers felt they fully/mostly under-
stood how to take the medication and what to do if side
effects occur. Some patients felt they only had a basic
understanding, and were not confident, of what to do
for side effect management. As these aspects could be
explained to the patient/carer by the Project Pharmacist
(e.g. during a home visit), the format and content was
kept consistent for the remainder of the PILs.
Four of the PILs (morphine, fentanyl, hydromorphone
and oxycodone) were translated in to seven languages
(Arabic, Greek, Italian, Sinhalese, Traditional chinese,
Vietnamese and Hindi) frequently encountered in the
SMR Palliative Care Consortium. This was done by
three translators (accredited by the National Accredita-
tion Authority for Translators and Interpreters, NAATI)
who are specialised and experienced linguists. The
translated material was independently checked.
Audio (MP3) files of the morphine leaflet were also
produced in English and in the seven other languages
above.
The PILs and MP3 files were attached to websites (e.g.
of the palliative care service, SMRPCC) for use by health
professionals to assist patients and carers in understand-
ing palliative care medications.
Communication strategy
A communication strategy for the Project Team, for
within the palliative care service, and for key stake-
holders, was developed. The Project Manager and Pro-
ject Pharmacist met with key stakeholders (e.g.
Pharmacy Guild of Australia, Pharmaceutical Society of
Australia, General Practice Divisions Australia, Palliative
Care Victoria) to discuss the project, how their organisa-
tion/network might be used to facilitate further
communication via e-mail, newsletters and articles, and
to provide, where relevant, education to their members
at information sessions.
Education strategy
The Project Pharmacist developed and provided educa-
tion to the palliative care service involved in the study,
as well to as other palliative care services and health
professionals (e.g. GPs) within the SMRPCC. Topics
covered included neuropathic pain, enteral administra-
tion of medications and prescribing in the elderly and in
renal and liver impairment.
Interprofessional education also occurred informally
during daily interactions between the Project Pharmacist
and other team members and formally at regular team
meetings.
The Project Pharmacist also taught patients and carers
to use a dose administration aid (DAA) for effective
medication management.
Phase 2: Implementation
The objective of this phase was to implement the activ-
ities discussed in Phase 1. Where necessary, adjustments
were made to these based on feedback from the Project
Team, External Evaluator, Steering Committee and key
stakeholders. The Project Pharmacist was also clinically
supervised, to a limited extent (because the Project
Pharmacist had considerable experience and expertise in
palliative care), by a Senior Medical Officer (doctor).
Interaction between the Senior Medical Officer and Pro-
ject Pharmacist involved, but was not limited to: joint
community visits, particularly when complex issues were
identified; follow up of patients’/carers’ concordance to
newly implemented medications/changes subsequent to
this; education of patients/carers; advice regarding suita-
ble drug formulations (e.g. for patients with swallowing
difficulties); post-medication review discussions (when
the Project Pharmacist had undertaken review sepa-
rately); development of resource charts (e.g. benzodiaze-
pine equivalence chart); auditing of patient’s current
medication regime (e.g. determining whether the medi-
cation list was recorded accurately/updated in the last
month); and auditing of the process of requesting emer-
gency medications from the GP (e.g. need for anticipa-
tory prescribing to manage symptoms on a 24 hour
“emergency” basis and need to have these medications
available in the home).
Phase 3: Evaluation
The objective of this phase was to evaluate the results of
the activities implemented in Phase 2, in order to enable
appropriate decision making and policy development by
government and the palliative care service regarding the
benefits of an ongoing role of a pharmacist in commu-
nity palliative care services in to the future:
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gories: process; impact; and outcomes. This meant
assessing the success of the process that underpinned
each activity implemented in the study in Phase 2; the
impact of each activity on the role of the Project Phar-
macist in the palliative care team; and the clinical out-
comes generated by each activity in terms of the
palliative care team’s knowledge and understanding of
medications, the number of patients screened as well as
medication reviews undertaken by the Project Pharma-
cist with a view to reducing DRPs, and the number of
clinical interventions made.
In addition to using the three categories above, evalua-
tion of the study was divided in to internal and external
arms that are described below.
Internal evaluation
These three categories were studied not just during
Phase 3, but also in earlier phases. During Phases 1 and
2 of the study, the Project Manager and Project Pharma-
cist regularly reviewed and revised its objectives and
timeframes as necessary, in consultation with the Project
Team and Steering Committee. The External Evaluator
also reviewed all of the processes and documents dis-
cussed in Phase 1, including statistical data collation and
analysis. As well, a 12-item survey was designed in
Phase 1 and sent as an online link to other team mem-
bers (n = 32) in Phase 2, to measure the number of
times the Project Pharmacist had been contacted, the
type of interactions and the considered value of the role
within the team. Open-ended comments could also be
made.
External evaluation
In Phase 3, the External Evaluator conducted a focus
group with the team (not including the Project Pharma-
cist or Project Manager) to further determine the effec-
tiveness of the study in terms of supporting the role of a
pharmacist in a community multidisciplinary palliative
care team. The focus group was conducted at the pallia-
tive care service, using a semi-structured guide, and was
audio recorded.
The results of the internal and external evaluations
were then combined and are shown in Table 1, accord-
ing to the program levels and indicators (in descending
order of level of evidence) adapted from Suvedi and
Morford (2003) [18] and according to each Phase of the
study in which they occurred.
Results
Project Pharmacist’s role
On review of the Project Pharmacist’s Activity Database,
it was demonstrated that the Project Pharmacist under-
took the following seven major roles [8]:
1. Medication review
2. Education for patients/carers e.g. carer training on
how to use DAAs and other delivery devices, such
as nebulisers and oxygen concentrators.
3. Ensuring ongoing access to medications e.g. home
delivery of medications in palliative care emergencies
4. Information provision/education for team mem-
bers e.g. on off-label medications, oral chemotherapy
or trial medications used by patients (this informa-
tion was inserted into the patient’s medical history
and “working file” for all team members to access)
5. Consultation and collaboration with team mem-
bers e.g. updating medication chart
6. Liaison with other health professionals (e.g. hospi-
tal, community and outreach pharmacists, GPs, pal-
liative care nurses) to ensure continuity of patient
care.
7. Symptom management protocol (e.g. on nausea
and vomiting, constipation) implementation through
in-services education.
In addition, the Project Pharmacist conducted a com-
bined bereavement visit (with a social worker) for a
patient’s carer. The Project Pharmacist found the experi-
ence to be valuable as it provided the opportunity for
interprofessional learning and development of this coun-
selling skill.
Impact of Project Pharmacist’s role in the team
Online survey
A 63% response rate was achieved (20/32 team mem-
bers). 50% of respondents (10/20) had interacted 10 or
more times with the Project Pharmacist, during the past
three months, for advice/assistance. Only 5% (1/20) had
never interacted with the Project Pharmacist; this
respondent was a non-clinical staff member who would
have been unlikely to have needed this type of contact.
The majority of interactions were regarding informa-
tion/clarification about medications (94.7%, 18/19),
advice on what medications could be used (73.7%, 14/
19) or advice on alternative medications (63.2%, 12/20).
Assistance in decision-making when changing a medica-
tion was less commonly sought (47.4%, 9/19). Com-
ments made by respondents also indicated that they
accessed the Project Pharmacist for other aspects of
medication management e.g. impact of medications on
functional status, minimising medications.
With regards to whether respondents found the Pro-
ject Pharmacist’s role helpful, all (20/20) felt that it had
improved their knowledge of the different medications
used in palliative care, 90% (18/20) indicated that it had
improved their knowledge of medication issues for pal-
liative care patients, and 60% (12/20) thought it had
changed their practice with sourcing and providing
information to patients/families. One respondent
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based care”.
The majority of respondents (95%) said they would be
more likely to discuss patients who had potential
medication issues with the Project Pharmacist. When
asked about how they found out information prior to
the role of the Project Pharmacist within the team, the
majority “found it themselves and/or approached the
Table 1 Combined results of internal and external evaluations of the study
Program Levels Indicators Results, including phase of the study and evaluation strategy
in which this was demonstrated
End results What long term changes occurred as a result of
the project?
￿ Improved knowledge of how/where to access information/
medications/management by the team (Phases 1 and 2, online
survey; Phase 3, focus groups)
￿ Increased knowledge of palliative care medications and their use
(Phases 1 and 2, online survey; Phase 3, focus groups)
￿ Development of PILs - available on website of palliative care
service (includes translations and MP3 files) (Phase 3)
￿ Care pathway developed (Phase 1)
￿ MRST developed (Phase 1)
￿ Toolkit for use by other palliative care services (Phase 3)
Changes in practice and
behaviour
How did practice change as a result of project
participation?
￿ Acceptance of the role of a pharmacist within a team (Phases 1
and 2, online survey; Phase 3, focus groups)
￿ Use of medication sheets in nursing folder for chemotherapy and
other medications (Phases 2 and 3)
￿ Documentation and process of obtaining emergency medications
- reviewed as part of audit (Phases 2 and 3)
Changes in knowledge,
attitudes, skills and
aspirations (KASA)
How did participants’ knowledge, attitudes, skills
and aspirations change as a result of project
participation?
￿ Increase in knowledge and skills of team with respect to
medications and their management, and on complexity of
medication regimens (Phases 1 and 2, online survey; Phase 3, focus
groups)
Reactions How did participants and clients react to the
project activities?
￿ Project Pharmacist accepted as an allied health professional within
the team (Phases 1 and 2, online survey; Phase 3, focus groups)
￿ Team very positive (Phases 1 and 2, online survey; Phase 3, focus
groups)
￿ Patients/carers accepting of the Project Pharmacist as part of the
team (Phase 2)
Participants Who participated and how many? ￿ Project Team, Steering Committee, External Evaluator, Team
members, staff working at the palliative care service (all involved in
consultation and communication strategies)
￿ 380 patients were screened using the MRST (Phases 2 and 3)
￿ 52 home visits to patients for medication review (Phases 2 and 3)
Activities In what activities did the participants engage
through the project?
￿ In-services to team (Phase 2)
￿ Education and information sessions for SMRPCC members and
health professionals working within this consortium and at another
consortium (Phase 2)
￿ Medication screenings using the MRST and medication reviews in
patients’ homes (Phase 2)
￿ Conferences and seminars (Phases 2 and 3)
￿ Consultation with key stakeholders (all Phases)
￿ Newsletter articles (all Phases)
Inputs Which personnel and other resources were used
during the project?
￿ Project Team/External Evaluator/Steering Committee (all Phases)
￿ Members of the team (all Phases)
￿ Staff working at the palliative care service (all Phases)
￿ Clinical supervision and support (Phase 2)
￿ Volunteers - assistance with reviewing and critique of PILs
(morphine) (Phase 2)
￿ Liaison with outreach pharmacists, clinical trial pharmacists, key
stakeholders (all Phases).
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the Hospital Pharmacy rarely received requests from the
team for information on medications or medication
management since the role of the Project Pharmacist
was introduced, and as a result, had “lessened the anxi-
ety” they had felt when providing advice for patients
w h ow e r ed e e m e dt ob ep a r to fa n‘invisible ward’ i.e.
patients who they had not seen but it was expected that
they were to provide information about their medica-
tions/treatments.
Focus group
Six team members participated in the focus group (1
Registrar [P1], 1 Occupational Therapist [P2], 1 Social
Worker [P3], 3 Nurses [P4-6]). When asked what they
perceived were the benefits of the Project Pharmacist’s
contributions towards medication screening and review,
participants felt that she was readily accessible,
approachable and knowledgeable, especially when called
on for information during home visits: “Great resource
and help especially when there’s a problem in the home,
can pick up the phone and ask [her] e.g. unfamiliar
drug, doses, calculations” (P4).
One participant (P5) stated that the Project Pharma-
cist was “confidence-building...helping give better service
and better outcomes for patient[s] especially because
[they] know [the] patient’sb a c k g r o u n d ”.A n o t h e r( P 3 )
commented that the Project Pharmacist: “picked up on
non-adherence and impact on behaviours”,a n d“made
[me] question about why it’s not always necessary to pre-
scribe emergency meds, need to be more client-centred,
emergency meds cost money. GPs aren’t always receptive
about emergency meds, and saying you’ve chatted to the
pharmacist helps with adding credibility/authenticity”.
Participants perceived that the Project Pharmacist’s
role had few limitations, mainly being that that it made
them ignore their own learning as they tended to rely
on her. When asked what areas required improvement,
participants believed that she should have been given
more opportunities to attend home visits and increased
time to dedicate to the role. Participants also felt it was
important that the Project Pharmacist “was participating
in team meetings in order to pick up on things and fol-
low up - this is a key component and would need to be
maintained in to future services”.
Aside from attending team meetings, participants
thought that to sustain this role in a community multi-
disciplinary palliative care team, a future pharmacist
needs to be “experienced and [have] a palliative care
approach to the way they think and interact with
families”. Participants believed that the model of care
piloted in the study was sustainable (and needed) as it
eliminated a gap in care that existed, was an “essential
component of interdisciplinary management for patients
being palliated at home”, where each component was
recognised as being important, and “provided a quality
service for patients and families” that involved reducing
the risk of medication misadventure and its potential
consequences:
“[It’s] about providing a safe service and acting
quickly e.g. on what GPs are prescribing, not necessa-
rily what’s wrong with our service”.
“Every community service should have a pharmacist”.
“Can expand positives to other teams, huge loss not
to have a pharmacist”.
Finally, to further ensure sustainability, participants
indicated that the gap between hospital to community
care needs to be bridged but were unsure about how
this could be done considering that the Project Pharma-
cist had been “proactive and education-focussed”.
Impact of Project Pharmacist’s role on clinical outcomes
Medication reviews
The Project Pharmacist Activity Database showed that
screening for patients at risk of medication misadven-
ture was conducted for the majority of patients (88.4%,
373/422) referred to the palliative care service, using the
MRST. 380 MRSTs were conducted from April 2009-
March 2010, during which the following problems were
frequently detected by the Project Pharmacist:
￿ 83% (316) took 5 or more medications, or more
than 12 doses of medications per day.
￿ 77% (294) took medication requiring monitoring,
had a narrow therapeutic index or are high risk.
￿ 62% (238) had other co-morbidities
￿ 55% (208) were recently discharged from hospital
￿ 59% (224) were attending different healthcare
providers
Allergies/adverse drug reactions were recorded routi-
nely since October 2009 in 185 MRSTs; 24% (44)
reported no known allergies/adverse drug reactions; 31%
(58) had none recorded; and 45% (83) had data
recorded. Similarly, renal function was routinely
recorded since December 2009 in 116 MRSTs. There
was data available for 49% (57) of patients.
Fifty two home visits were undertaken by the Project
Pharmacist from June 2009-March 2010, and these were
done on a “needs basis” after consultation with other
team members. Approximately 6 home visits per month
were undertaken by the Project Pharmacist, and on
average, a home visit took 54.5 minutes. Where there
was no need for a home visit, sometimes care was coor-
dinated by the Project Pharmacist over the telephone, or
by other means, which took substantial time; this was
not counted as a home visit.
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home visits (88%, 46/52), and a report of the findings
was generated for all patients seen by the Project Phar-
macist, a copy of which was compiled into the patient’s
medical history and sent to their GP, community phar-
macist and other health professionals involved in the
patient’s care if appropriate.
The Project Pharmacist perceived the medication
reviews undertaken at home visits to have had a signifi-
cant impact on patients’ care, through reassurance and
education around medication management for patients/
carers. She felt that the impact of medication reviews on
team members was that they were provided with an
updated medication list for all patients, and therefore
knew exactly what medications the patient was currently
taking.
Interventions
The Project Pharmacist made 113 interventions based
on the same number of DRPs that were detected, and
the most common DRPs were “patient requests drug
information” (25%, 28/113) and “condition not ade-
quately treated” (22%, 25/113). The Project Pharmacist
made 120 recommendations in relation to her interven-
tions, and the most common types were “referral to the
prescriber” (35%, 42/120) and “education/counselling
session” (30%, 36/120).
It could not be estimated, however, as to how many
recommendations arising from medication reviews were
accepted by prescribers, as the Intervention tool was
used infrequently, and there was little correspondence
from GPs in response to the Medication Review Reports
generated by the Project Pharmacist. A lot of the time
though symptom management issues were managed by
doctors at the palliative care service and scope for GP
involvement was small; the purpose of the Medication
Review Report was mainly to keep the GP up-to-date
with the patient’s progress. Also, in many cases the
Medication Review report only recorded the patient
education activities undertaken by the Project Pharma-
cist, where no GP intervention was required.
Toolkit
A toolkit was developed to assist other palliative care
services in developing their own model of care, incor-
porating the role of a specialist pharmacist in to the
team. Four options for sustainability were provided, as
well as some “rough” costings for this role in to the
future. Pathways/strategies and tools that were devel-
oped in this study, such as the care pathway, MRST,
Intervention tool and PILs, were also included in the
toolkit.
Discussion
This study is the first in Australia to demonstrate that
the inclusion of a pharmacist in a community palliative
care multidisciplinary team: assists in increasing the
knowledge of team members, with respect to medica-
tions used in palliative care and their management;
leads to improved knowledge of potential problems with
medications and how to manage them and to a change
in practice for the benefit of patients; enables ongoing
education and support from the pharmacist to the team
members; allows for in-service education to be provided,
as and when required; assists in improving contacts with
the GPs and palliative care service for the benefit of the
patient and their carer; and assists the patient and carer
to better understand the medications prescribed.
In particular, the study led to a significant increase
and improvement in knowledge of medications and
their use by nursing staff. However, this result may in
part be influenced by the role of the Senior Medical
Officer in the team and their contribution to patients’
medication management in concert with that of the Pro-
ject Pharmacist’s. Certainly, improving health profes-
sionals’ knowledge of, and skills and confidence in
medication utilisation has been recognised as key strat-
egy in preventing medication misadventure and improv-
ing patient safety [19,20], especially in older and non-
English speaking persons [21]. In line with recommen-
dations made by Westberg and Sorensen [21], the Pro-
ject Pharmacist considered the impact of language
barriers when working with patients and carers to opti-
mise their medication management. PILs for four medi-
cations in seven languages other than English were also
designed for this purpose; however, were only developed
in the final phase of the study and thus were not utilised
by the Project Pharmacist. The PILs can potentially be
used to assist medication management in community
palliative care settings and further research is required
to determine their face and content validity from the
consumer perspective and whether they meet their edu-
cational, language and visual needs [22,23].
The study findings in terms of number of DRPs
detected (113) by the Project Pharmacist are also com-
parable to those reported by Westberg and Sorensen
[21]. In their study, the pharmacist detected 186 DRPs;
these were greater among non-English speaking patients
(31%) than English speaking patients (12%), and drug
therapy outcomes improved by 24% once the pharmacist
joined the team of clinic providers [21]. In another study
by Needham, Wong and Campion, community pharma-
cists’ interventions’ in palliative care were assessed for
significance [24]; in contrast, the study reported here
did not assess the significance of the Project Pharma-
cist’s interventions but rather, looked at the number of
recommendations made (120) in relation to her inter-
ventions (113), which were readily accepted by doctors
and other health professionals in the palliative care
team. These results confer with those reported by
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cist’s interventions were accepted by physicians [12].
The study presented here is also the first to have
reported the utility of a screening tool (MRST) in the
palliative care population and therefore the first to pre-
sent data on the number of patients screened (373/422)
for being ‘at risk’ of medication misadventure. The num-
ber of home visits made by a pharmacist to undertake
medication reviews for patients requiring palliative care
(46/52) is also new data that is currently not available in
the literature. This tool and measurement outcome,
respectively, can reasonably be used in future studies
where a pharmacist is involved, in addition to assessing
the achievement of clinical outcomes such as symptom
control [12,25] and an improvement in patients’ and
carers’ medication related knowledge and understanding
[26].
Although the timeframe of the study and the capacity
to measure benefits was limited, it was recognised that
the inclusion of a pharmacist could also lead to: an
increase in confidence of patients/carers in the use of
medications; an increase in medication concordance; a
reduction in medication errors made by both health
professionals and patients/carers; and reduced hospital
admissions due to medication errors being averted by a
comprehensive patient screening and medication review
process, recognising that hospital admissions are some-
times required to improve medication and/or symptom
management and can, ultimately, prevent future admis-
s i o n sa st h ep a t i e n t ’s condition deteriorates. This is in
line with the findings from a study by Ajdukovic et al,
who found that pharmacist elicited medication histories
for ‘at risk’ groups in the Emergency department can
reduce medication misadventure and errors [27].
Specifically, this role in the present study alleviated
the demand on the hospital pharmacists by having many
of the team’s queries regarding medications or medica-
tion management issues answered by the Project Phar-
macist. This was a saving in time and money to this
area of hospital operations. However, this also could not
be quantified as previous requests for assistance varied
in number and complexity. ‘Interruptions’ to the usual
role of the hospital pharmacists also varied depending
on whether they were in the pharmacy at the time of
the request and so information was on hand, or whether
they were on a ward and had to leave the task they
were undertaking and return to the pharmacy to seek
information to assist.
Importantly, this study attempted the development of
a potentially cost-effective model of care (incorporating
various pathways/strategies and tools), which has not
been previously done locally or internationally. The care
pathway provided a focus and framework for the Project
Pharmacist, the team and the palliative care service, and
is freely available to other palliative care services across
Melbourne, Victoria for duplication via the toolkit that
was developed. This toolkit should be added to the Aus-
tralian Government Department of Health website for
use by community palliative care services across Austra-
lia, and if appropriate, to international government web-
sites. Indeed, its encompassing tools became familiar
within the study community palliative care service and
referrals increased. All patients were screened by the
Project Pharmacist on admission to the team, to evalu-
a t et r i g g e r sf o rh o m ev i s i t sa n dam o r ee x t e n s i v em e d i -
cation review.
Although the development of a cost-effective model of
service delivery was a component, this premise was
unable to be achieved within the scope of the study
because the structure of each palliative care service is so
different. The community palliative care service was
aided by the existence of a hospital pharmacy depart-
ment that had the capacity to provide back-up to the
Project Pharmacist. The pharmacy department and Pro-
ject Pharmacist complemented each other. This addi-
tional support is not available in most community
palliative care services. Further, a lack of pharmacists
with the high level of knowledge and skills relevant to
palliative care of the Project Pharmacist engaged for this
s t u d ya r eu n l i k e l yt ob ea b l et ob ed u p l i c a t e d ,a tt h i s
point in time, in other community palliative care
services.
There is the potential, however, to duplicate the
model and make a saving on the employment costs by
sharing a community pharmacist among a group of pal-
liative care services. This would aid the potential for a
cost-effective model because of the reduction in time
spent with families once the pharmacist was involved; a
lessening in the prescribing of unnecessary and/or inef-
fective medication; and an improvement in the overall
knowledge of the other health practitioners and patients
and families in recognising adverse effects of medicines
and thus anticipating medication and treatment needs,
with a subsequent improvement in the care and support
of patients and their families.
There would need to be the engagement of more than
one pharmacist in one service to more accurately pre-
dict a cost-effective model. This study could therefore,
more realistically, be viewed as a scoping or feasibility
study.
Further to the above, the model of care is not a ‘one
size fits all’ paradigm and should be clearly seen in the
context of location and requirements. A pharmacist
employed in a single palliative care service, for example,
may have a different role and structure from other
employment models e.g. compared with employment by
a palliative care consortium or within a division/network
of GPs. Nevertheless, below are examples of
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model of care; some or all of these could be considered
by policy makers, palliative care services, divisions/net-
works of GPs, community/specialist pharmacists and
pharmacy peak bodies in other states of Australia and
overseas.
Potential future of the role of pharmacists within
palliative care services
As a result of this study, a number of recommendations
and suggestions have been made that would assist deci-
sion-making on the efficacy of including a pharmacist
within community palliative care services. These include
recommendations regarding funding, region-wide or
consortia collaborative arrangements and inclusion of a
pharmacist within divisions/networks of GPs.
It was considered that funding should be made avail-
able for a specialist pharmacist to be placed in commu-
nity palliative care services within Melbourne, Victoria.
This would assist continuation of the ‘value-add’ and
lessons learned from this feasibility study across the sec-
tor. Inclusion in the palliative care service would provide
timely access to expertise, education and advice as well
as improve patient medication management and symp-
tom control.
Both government and palliative care services them-
selves should consider how this might be achieved. An
agreement between palliative care services could be
negotiated within the palliative care consortia or regions
to fund a pharmacist position to support the services to
improve medication management for their patient group
and also knowledge of palliative care medications and
their management within their community palliative
care teams. A pharmacist placed within a consortium
would need to incorporate all the skills required within
a single service, but be broadened out in terms of actual
tasks undertaken and service operation. This would
require the capacity to manage the varying demands of
the service within a region, and the compilation of an
education information portfolio, including online access
to information and support, to assist the various
demands upon the time and knowledge of the
pharmacist.
Alongside this, the pharmacist would need to remain
up-to-date with changing referral processes and their
relevance to palliative care patients. An essential compo-
nent of such an arrangement would have to be a will-
ingness by both the services and the pharmacist to be
mobile. By its nature, the role of a pharmacist across a
consortium or region would be less hands-on than one
placed within a single service.
To aid improvement in symptom management and
control by community palliative care services, there
should be an extension of, the current limited funding
of Outreach Pharmacy Services within public hospitals
a n di ts h o u l de n s u r et h a tp a l l i a t i v ec a r ep a t i e n t sa r e
included within their scope of operation. Outreach Med-
ication Reviews are available at major metropolitan hos-
pitals in Victoria for patients at risk of medication
misadventure after discharge from hospital. The Out-
reach Pharmacist provides counselling on medication
and disease state management in the patient’sh o m eo r
specialist outpatient clinic. After a home visit, a report
is sent to the patient’s GP and community pharmacist.
The extension of the capacity of the Outreach Pharmacy
Services could provide an avenue for palliative care
patients to obtain a medication review in a timely man-
ner after discharge from hospital.
Divisions/networks of general practice should also
consider incorporation of a specialist palliative care
pharmacist within their division/network. The pharma-
cist’s role would be different if located within a division/
network of GPs, although much of the above would be
required, and it could be assumed that the tasks would
be broader than providing palliative care. Inclusion in
this forum would allow for improved collaboration
between hospitals and community palliative care services
within these network areas.
At the same time, better links between peak pharmacy
and palliative care bodies, with an accompanying
improvement in communication between community
pharmacists and palliative care services, would greatly
assist in the support of patients and their families, espe-
cially in accessing, using and managing emergency just-
in-case medications. This was recognised as an issue in
this study and further research in to prescribing and dis-
pensing of emergency medications is required to prevent
duplication and wastage; specifically, to determine
whether this results in an accompanying decrease in
hospital admissions and what cost savings could be
achieved by interventions resulting from HMRs for pal-
liative care patients.
The development of a PIL for patients and carers on
the use of emergency medications could also assist in
alleviating concerns by patients and their families on
how and when to take them. A generic document for
use by palliative care services could be developed (with
relevant local service adaptations incorporated as
required) that can be sent to GPs, which includes all the
relevant details required by the GP, including the form,
strength, dose and cautions associated with emergency
medications and who to contact if patient/family are
unsure of how and what to do.
The development of a check list for nursing staff on
the process of ordering emergency as well as regular
medications, including follow-up processes and, an
improvement in communication from palliative care ser-
vices to GPs and patients regarding their use, would all
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a reduction in hospital admissions and the capacity for
patients to die at home if they desire. Anecdotally, how-
ever, it is reported that no matter how much planning
and information is provided, some patients, carers and
families can, understandably, panic and require outside
assistance when faced with an emergency medication
related problem.
Limitations
Patients or carers were not surveyed with respect to
their knowledge (to determine the impact of the Project
P h a r m a c i s to nt h i s ) ,b e c a u s eo f t e nb yt h et i m et h eP r o -
ject Pharmacist had screened medications and/or visited
the patient, their condition had deteriorated to the
extent that surveying would have been an imposition.
Occasionally, patients had died before the Project Phar-
macist had a chance to undertake a home visit.
Conclusions
This study showed that the inclusion of a pharmacist in
a community multidisciplinary palliative care team has
great benefits for the team, patients and carers. There
are seven major roles that a pharmacist can undertake,
which can lead to an increase in the medication-related
knowledge and skills of team members and thereby
improve the medication and symptom management of
patients and minimise medication errors. To support
these roles a model of care is required and was created,
incorporating various pathways/strategies and tools that
can potentially be duplicated by other palliative care ser-
vices. A larger, longitudinal study is required to accu-
rately test whether this is a cost-effective model,
incorporating a number of different modus operandi, for
example, a pharmacist within a single service versus a
pharmacist across consortia or one placed within a net-
work/division of GPs.
From this feasibility study, it could be extrapolated
that the cost-effectiveness of such a model would be
demonstrated by the improved knowledge of medica-
tions and their use by both professionals and patients/
families, and thereby better symptom identification and
management, along with improved patient medication
information and better communication between pallia-
tive care services, GPs, specialists and pharmacists. A
foreseeable outcome would be fewer hospital admissions
for the palliative care patient and a reduction in pre-
scribing of unnecessary medications.
Additional material
Additional file 1: Medication Review Screening Tool (MRST). This is
the tool that was developed in the study for use by the pharmacist to
assist them with screening patients who were admitted to the palliative
care service to determine their risk of medication misadventure.
Additional file 2: Intervention form. This is the tool that was
developed in the study for use by the pharmacist to assist them with
recording drug-therapy problems they detected in patients and
recommendations they made to resolve those problems.
List of abbreviations used
CMI: Consumer medicine information; DAAs: Dose administration aids; DRP:
Drug related problem; D.O.C.U.M.E.N.T: Drug selection, Over or underdose;
rescribed, Compliance, Untreated indications, Monitoring required, Education
or Information, Non-clinical, and Toxicity or adverse reaction; GPs: General
Practitioners; MRST: Medication review screening tool; NAATI: National
Accreditation Authority for Translators and Interpreters; PIL: Patient
information leaflet; SMRPCC: Southern Metropolitan Region Palliative Care
Consortium.
Acknowledgements and funding
This study was an initiative of the Department of Health and was funded by
the Australian Government, Department of Health and Ageing, under the
National Palliative Care Program. The study was undertaken at Calvary Health
Care Bethlehem, Victoria. The funding body provided a framework for the
study, and neither had a role in the collection, analysis and interpretation of
data, nor in the writing of this manuscript and in the decision to submit it
for publication.
The authors would like to thank the team members, Project Team, Steering
Committee, key stakeholders and Clinical Supervisor for their valuable input
and support. Also thanks to the medical staff and volunteers of the service
who assisted in the development of the PILs and the patients and carers
who allowed us in to their homes as part of the team.
Author details
1Centre for Medicine Use and Safety, Faculty of Pharmacy and
Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052,
Melbourne, Australia.
2c/o Calvary Health Care Bethlehem, Kooyong Road,
Caulfield South, Melbourne, Australia.
3PO Box 205, Sandringham, Melbourne,
Australia.
Authors’ contributions
SH drafted the manuscript and made contributions to the conception and
design of the study, as well as the collection (specifically for the focus
group), analysis and interpretation of data. MB contributed to the design
and coordination of the study; the acquisition (specifically for the online
survey), analysis and interpretation of data; and revised the manuscript. SS
also collected (specifically for the medication reviews and interventions),
analysed and interpreted the data, and revised the manuscript. All authors
have read and approved the final manuscript.
Authors’ information
SH graduated from Monash University (BPharm(Hons) in 2001 and PhD in
2007) and was appointed to the position of Lecturer in 2009 at the Faculty
of Pharmacy and Pharmaceutical Sciences. She is an Early Career Researcher
in Pharmacy Practice with research experience and expertise in professional
practice, education and medication safety and use, particularly in the area of
palliative care service delivery in the primary care setting. Her PhD research
involved the identification of Australian community pharmacists’ educational
needs in palliative cancer care, and the subsequent development, delivery
and evaluation of an educational program to meet these needs. This
program will soon be adapted to suit a Masters in Pharmacy Practice
program at Monash University for postgraduate students. SH also teaches
palliative care to undergraduate students at Monash University along with
other topics, and has a strong research interest in women’s health.
MB was Executive Director of Palliative Care Victoria and on the Palliative
Care Australia Council for several years. Her involvement with the palliative
care sector has encompassed many roles. Since living in Thailand for some
years, Margaret returned to Australia and managed a number of projects,
including Development of a Model of Care for People Living with Motor
Neurone Disease. She has recently left Australia to live overseas again.
Hussainy et al. BMC Palliative Care 2011, 10:16
http://www.biomedcentral.com/1472-684X/10/16
Page 11 of 12SS has practical experience in palliative care in hospital and community
settings, and has undertaken postgraduate studies in palliative care. She was
a member of the expert group who updated the Therapeutic Guidelines:
Palliative Care version 3, 2010. SS has had input in to two projects funded
by the Australian Government Department of Health and Ageing, which
were aimed at improving the medication management of palliative care
patients by educating community pharmacists. She is currently assisting
development of the palliative care unit for postgraduate study at Monash
University.
Competing interests
The authors declare that they have no competing interests.
Received: 28 March 2011 Accepted: 31 October 2011
Published: 31 October 2011
References
1. Council of Palliative Care Australia: Palliative Care Service Provision in
Australia: A Planning Guide. 2 edition. Australian Capital Territory: Council of
Palliative Care Australia; 2003.
2. Clinical Oncology Society Of Australia, The Cancer Council Australia,
National Cancer Control Initiative: Optimising Cancer Care in Australia
Melbourne: National Cancer Control Initiative; 2002.
3. Doyle D, Hanks GWC, MacDonald N: Oxford Textbook of Palliative Medicine. 2
edition. New York: Oxford Medical Publications, Oxford University Press Inc;
1998.
4. Armes PJ, Addington-Hall JM: Perspectives on symptom control in
patients receiving community palliative care. Palliat Med 2003,
17(7):608-15.
5. Calvary Health Care Bethlehem: Pharmacist in Community Palliative Care
Multidisciplinary Team Pilot Project Melbourne: Department of Health; 2010.
6. Campbell Research & Consulting Pty Ltd: Home Medicines Review Program
Qualitative Research Project Final Report Melbourne: Department of Health;
2010.
7. Ziebland S, Chapple A, Dumelow C, Evans J, Prinjha S, Rozmovits L: How
the internet affects patients’ experience of cancer: a qualitative study.
BMJ 2004, 328:1-6.
8. Hussainy SY: Community Pharmacists and Palliative Cancer Care:
Addressing Educational Needs. PhD thesis Monash University, Department
of Pharmacy Practice; 2006.
9. Mitchell G, Bowman J, McEniery J, Eastwood H: The Blue Book of Palliative
Care: Evidence based Clinical Guidelines for Primary Practitioners. 3 edition.
Australian Capital Territory: Commonwealth Department of Health and
Aged Care; 1999.
10. Ventafridda V: According to the 2002 WHO definition of palliative care.
Palliat Med 2006, 20(3):159.
11. Walker K: Role of the pharmacist in palliative care. Progress in Palliative
Care 2010, 18(3):132-139.
12. Wilson S, Wahler R, Brown J, Doloresco F, Monte S: Impact of pharmacist
intervention on clinical outcomes in the palliative care setting. American
Journal of Hospice and Palliative Medicine 2010.
13. Australian Government Department of Health and Ageing: Guiding
principles for medication management in the community - July 2006.
[http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-guide-
medmgt-jul06-contents~nmp-guide-medmgt-jul06-guidepr6].
14. Pit S, Byles J, Cockburn J: Medication review: patient selection and
general practitioner’s report of drug-related problems and actions taken
in elderly Australians. J Am Geriatr Soc 2007, 55(6):927-934.
15. Currow D, Stevenson J, Abernethy A, Plummer J, Shelby-James T:
Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007,
55(4):590-595.
16. Fick D, Cooper J, Wade W, Waller J, Maclean J, Beers M: Updating the
Beers criteria for potentially inappropriate medication use in older
adults: results of a US consensus panel of experts. Arch Intern Med 2003,
163(22):2716-24.
17. Peterson G, Liauw C, Elkerton J, McKenzie D, Fitzmaurice K: The
Development and Evaluation of a Computerised System for the Provision and
Documentation of Pharmacists’ Cognitive Services Hobart: University of
Tasmania; 2003.
18. Suvedi M, Morford S: Conducting Program and Project Evaluations: A Primer
for Natural Resource Program Managers in British Columbia Karnloops: Forrex
- Forrex Research Extension Partnership; 2003.
19. Benjamin D: Reducing Medication Errors and Increasing Patient Safety:
Case Studies in Clinical Pharmacology. J Clin Pharmacol 2003,
43(7):768-83.
20. Regnard C, Hunter A: Increasing prescriber awareness of drug
interactions in palliative care. J Pain Symptom Manage 2005, 29(3):219-21.
21. Westberg S, Sorensen T: Pharmacy-related health disparities experienced
by non-English speaking patients: impact of pharmaceutical care. JA m
Pharm Assoc (2003) 2005, 45(1):48-54.
22. Raynor D, et al: A systematic review of quantitative and qualitative
research on the role and effectiveness of written information available
to patients about individual medicines. Health Technol Assess 2007, 11(5):
iii, 1-160.
23. Docherty A, Owens A, Asadi-Lari M, Petchey R, Williams J, Carter Y:
Knowledge and information needs of informal caregivers in palliative
care: a qualitative systematic review. Palliat Med 2008, 22(2):153-171.
24. Needham DS, Wong IC, Campion PD: Evaluation of the effectiveness of
UK community pharmacists’ interventions in community palliative care.
Palliat Med 2002, 16(3):219-25.
25. Lorenz K, Rosenfeld K, Wenger N: Quality indicators for palliative and end-
of-life care in vulnerable elders. Journal of the American Geriatrics Society
2007, 55(S2):S318-S326.
26. Hussainy S, Marriott J, Nation R: Assessing medication knowledge of
Australian palliative cancer care patients and carers, and their
interactions with pharmacists. Palliat Med 2009, 12(9):769.
27. Ajdukovic M, et al: Pharmacist elicited medication histories in the
Emergency Department: Identifying patient groups at risk of medication
misadventure. Pharmacy Practice 2007, 5(4):162-8.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-684X/10/16/prepub
doi:10.1186/1472-684X-10-16
Cite this article as: Hussainy et al.: Piloting the role of a pharmacist in a
community palliative care multidisciplinary team: an Australian
experience. BMC Palliative Care 2011 10:16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hussainy et al. BMC Palliative Care 2011, 10:16
http://www.biomedcentral.com/1472-684X/10/16
Page 12 of 12